Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma

<div>Clinical predictive value of the prognostic model. (a) Sensitivity to chemotherapeutic agents between the high-risk subtype and low-risk subtype. (b) GSVA of differentially expressed genes in the high- and low-risk groups. (c) GSEA of differentially expressed genes in the high- and low-risk groups. (d) The map of mutations for high- and low-risk groups.</div>

Analytical Cellular Pathology

fig7

Figure 7

Figure 7: Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma 

Figure 7 | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma 